Full-Time

National Field Training Manager

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$165k - $180kAnnually

Senior

Remote in USA

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • Proven track record of field sales success
  • Excellent presentation and facilitation skills
  • Experience coaching and training field-based sales representatives is desired
  • Strong organizational skills with ability to manage multiple projects simultaneously and prioritize travel requirements
  • Bachelor's degree
  • 5+ years sales experience
  • 1+ years of field training experience
  • Applicants must be currently authorized to work in the United States on a full-time basis.
Responsibilities
  • Conduct regular field rides to ensure appropriate and effective execution and pull-through of training/marketing/sales initiatives
  • Aid the Director, Learning & Development, in the development of overall product training frameworks, programs, content, collateral, and rollout plans to increase sales force skills and knowledge with the goal of positively impacting sales results
  • Assist in the execution of all Commercial training programs, including but not limited to new-hire onboarding, product training, industry updates, competitive landscape reviews, and sales skill development to ensure the maximum effectiveness of the sales force
  • Facilitate workshops and training classes on subjects including, but not limited to, those listed above
  • Partner with Sales Management, and Regional Training Liaisons (RTLs) to assess training gaps and work one-on-one in the field with our Clinical Specialists to address those gaps
  • Assist in the planning and execution of National Field Meetings to align the Field Salesforce with current customer perspectives and Marketing brand goals
  • Facilitate ongoing distance learning programs in order to increase field competencies while minimizing time spent away from customers
  • Maintain a high level of business intelligence, including new training methods, training programs and best practices
  • Comply with all laws, regulations, and policies that govern the conduct of Corcept activities
  • 50% Travel required

Corcept Therapeutics focuses on developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to improve understanding and care for cortisol-related conditions. The goal of Corcept is to advance the treatment of serious medical conditions linked to cortisol imbalance.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.

Help us improve and share your feedback! Did you find this helpful?